A new AI tool can identify which men with prostate cancer would benefit from the drug abiraterone, which significantly reduces mortality risk for some patients. The study, led by UK researchers, highlights the importance of tailoring treatments to avoid unnecessary side effects and improve health outcomes. The findings were presented at a conference in Chicago, and researchers urge the NHS to reconsider access to abiraterone for more patients. Teljes cikk (Euronews.com)